Menu
Home
Chi siamo
Provider ECM
Certificazione qualità
La nostra formula
Lavora con noi
News
Video gallery
Congressi/Iscrizioni
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Contatti
3
rd
POSTGRADUATE
Lymphoma Conference
Home
Slides
Thursday, March 23, 2017
Session I: Mantle Cell Lymphoma
Chairmen:
M. Dreyling, P. Martin
New research issues
S. Chen-Kiang
Front-line treatment in young patients:
European perspective
M. Dreyling
Front-line treatment in young patients:
American perspective
P. Martin
Front-line treatment in young patients:
Role of maintenance therapy
S. Le Gouill
Round Table - Relapsed/refractory setting:
Lenalidomide
P. Martin
Round Table - Relapsed/refractory setting:
Temsirolimus
G. Hess
Round Table - Relapsed/refractory setting:
Bortezomib
O.A. O’Connor
Round Table - Relapsed/refractory setting:
Allotransplant
O. Hermine
Newer agents:
Acalabrutinib
S. Rule
Newer agents:
Venetoclax
S. Le Gouill
Newer agents:
Palbociclib
P. Martin
Newer agents:
BGB-3111
S. Rule
Session II: Hodgkin Lymphoma
Chairman:
A. Younes
Relapsed/refractory setting:
Brentuximab Vedotin
A. Younes
Relapsed/refractory setting:
Nivolumab
S.M. Ansell
Relapsed/refractory setting:
Pembrolizumab
R. Chen
Response criteria on checkpoint inhibitors treatment
B.D. Cheson
Autotransplant and beyond
C.H. Moskowitz
Friday, March 24, 2017
Session III: Follicular Lymphoma
Chairman:
B.D. Cheson
WHO news
S.A. Pileri
Epigenetic news in follicular lymphoma
A.M. Melnick
Transformed follicular lymphoma:
biology and treatment
B.L. Link
New biological agents
(single agent and combo):
PI3K inhibitors
A. Younes
New biological agents
(single agent and combo):
BTK inhibitors
B.D. Cheson
New biological agents
(single agent and combo):
BCL-2 inhibitors
J. Gerecitano
New anti-CD20 monoclonal antibodies
C. Buske
Biosimilar rituximab
W. Jurczak
Session IV: Diffuse Large B-Cell Lymphoma
Chairman:
A.M. Carella
Debate - Primary mediastinal lymphoma:
R-DA-EPOCH
W. Wilson
Debate - Primary mediastinal lymphoma:
I-II-III generation chemotherapy regimens
A. Davies
Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas:
Molecular data
A. Traverse-Glehen
Double-hit and double-protein-expression lymphomas: aggressive and refractory lymphomas:
Clinical presentation
B.L. Link
Plasmoblastic lymphoma
J.J. Castillo
New agents
S.M. Ansell
